Whenever HbA1c is above target despite dual therapy in T2D adults with eGFR ≥ 60 mL/min/1.73 m2 plus albuminuria (≥ 200 mg/g) or with eGFR 30–59 mL/min/1.73 m2, triple therapy with metformin, SGLT2i, and GLP-1 RA IS RECOMMENDED to reduce renal outcomes and to improve glycemic control. Here, GLP1R is linked to type 2 diabetes mellitus.